An Early Phase 1 interventional study of Hyaluronic Acid- corticosteroid- 5% glucose in Carpal Tunnel Syndrome (CTS), sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Tanta University · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Carpal Tunnel Syndrome with a site in Egypt — 21 open to participants now, 23 under way, 1 of them phase 3. Carpal Tunnel Syndrome · Egypt.
Among the 64 studies in Carpal Tunnel Syndrome with a site in Egypt, this one is the 21st largest by planned enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 17 of the 22 other live ones, and was the 64th registered.
589 studies on the registry are indexed under Carpal Tunnel Syndrome; 134 are open to participants now.
Browse Carpal Tunnel Syndrome studies →21 of the 64 studies in Carpal Tunnel Syndrome with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 20–40
Kafrelsheikh University · Sites in Egypt
Ages 18+
Sohag University · Sites in Egypt
Ages 18–60
Osama Ahmed Elshafei · Sites in Egypt
Ages 18–65
Cairo University · Sites in Egypt
Ages 40–60 · Women only
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 73 Carpal Tunnel Syndrome studies recruiting now, 27 (37%) set no upper age limit and 37 (51%) stop at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 2 · Phase 4 3
First in 2016; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 444 interventional studies indexed under Carpal Tunnel Syndrome.
Median enrollment 60 across the 53 interventional studies, 50 across the 11 observational. Of the 30 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 64 have an industry lead sponsor. The 10 most frequent:
Tanta University is the lead sponsor of 1,013 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Tanta University has 4 studies filed under Carpal Tunnel Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Carpal Tunnel Syndrome with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07700316Delta University for Science and TechnologyCompare the Effect of Radiofrequency (TECAR) and Ultrasound on Sensation, Hand Dexterity, and Quality of Life in Patients With Carpal Tunnel Syndrome. | 2026-12-31 |
| NCT07539480Middle East UniversityPain Neuroscience Education Versus Kinesio Tape on Functional Outcomes in Patients With Carpal Tunnel Syndrome | 2027-09-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 64 studies in Carpal Tunnel Syndrome with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Carpal tunnel syndrome (CTS) is a common peripheral nerve entrapment disorder caused by compression of the median nerve at the wrist. This study is a comparative study designed to evaluate the efficacy of three ultrasound-guided injection treatments for patients with mild to moderate CTS: hyaluronic acid (HA), corticosteroid, and 5% glucose (D5W).
A total of 60 adult patients with clinically and electrophysiologically confirmed mild to moderate CTS will be enrolled and divided into three groups of 20 patients each. Participants will receive a single ultrasound-guided injection using one of the three study interventions. Clinical assessment will include Phalen's test and Tinel's sign. Electrophysiological assessment will include median nerve sensory and motor nerve conduction parameters, while ultrasonographic assessment will include measurement of the median nerve cross-sectional area.
Participants will be reassessed three months after the intervention using the same clinical, electrophysiological, and ultrasonographic measures. The study will compare changes in these outcomes among the three treatment groups to evaluate their relative efficacy in the management of mild to moderate CTS.
Detailed Description
Carpal tunnel syndrome (CTS) is the most common peripheral nerve entrapment syndrome and results from compression of the median nerve as it passes through the carpal tunnel at the wrist. The carpal tunnel is a relatively narrow osteofibrous canal containing the median nerve and nine flexor tendons. Any condition that decreases the available space within the tunnel or increases the volume of its contents may increase intracarpal pressure and compromise median nerve function.
The clinical severity of CTS can range from mild to severe. Mild CTS is generally characterized by intermittent sensory symptoms and sensory conduction abnormalities, whereas moderate CTS may involve both sensory and motor nerve conduction abnormalities. Severe disease may be associated with persistent numbness, weakness, thenar muscle atrophy, and evidence of more advanced nerve damage. The present study will focus on patients with mild to moderate CTS, confirmed clinically and electrophysiologically.
Conservative management of CTS includes wrist splinting, physiotherapy, and local injections. Corticosteroid injection is an established treatment option that can provide short-term symptomatic relief. More recently, other injectates have been investigated. Hyaluronic acid (HA) has been proposed as a treatment that may reduce perineural adhesions and improve median nerve gliding. In addition, perineural injection and hydrodissection using 5% glucose (D5W) have shown promising results in patients with neuropathic pain conditions, including CTS.
Ultrasound guidance will be used for all injections. Ultrasound guidance allows visualization of the median nerve and surrounding anatomical structures during the procedure and facilitates accurate placement of the injectate while avoiding direct injury to the median nerve. Ultrasonography will also be used to measure the median nerve cross-sectional area (CSA), providing an objective structural parameter for assessment and follow-up.
Study Objective
The primary objective of this comparative study is to evaluate and compare the efficacy of ultrasound-guided injections of hyaluronic acid, corticosteroid, and 5% glucose in patients with mild to moderate CTS. Treatment response will be evaluated using clinical, electrophysiological, and ultrasonographic findings.
Study Population and Design
The study will be conducted in the Department of Rheumatology, Rehabilitation, and Physical Medicine at Tanta University Hospitals. A total of 60 adult patients with mild to moderate CTS will be included. Participants will be divided into three treatment groups, with 20 patients in each group.
Eligible participants will be adults aged 18-70 years with clinical symptoms of CTS lasting at least 6 weeks and electrophysiological confirmation of mild to moderate CTS. All participants must be able to provide informed consent.
Patients will be excluded if they have received an injection into the same wrist within the previous 6 months, have undergone previous carpal tunnel surgery, have severe CTS characterized by absent sensory potentials or electromyographic evidence of denervation, or have local infection or coagulopathy.
Baseline Assessment
Before treatment, all participants will undergo a baseline assessment. This will include a full medical history and comprehensive neurological and musculoskeletal examination of the wrist.
Clinical assessment will include:
Phalen's test. Tinel's sign.
Electrophysiological assessment will be performed using nerve conduction studies (NCS), including:
Median sensory distal amplitude and conduction velocity. Median motor distal latency and amplitude. Maintenance of limb temperature at or above 32°C during the examination.
Ultrasound examination will be performed to determine the cross-sectional area of the median nerve using tracing of the inner hyperechoic rim of the epineurium.
Intervention Procedures
All injections will be performed under sterile conditions with ultrasound guidance. The participant will be positioned either supine or seated with the forearm supinated. The ultrasound probe will be positioned transversely over the inlet of the carpal tunnel, and an in-plane ulnar approach will be used. Particular care will be taken to avoid piercing the median nerve.
Participants will receive one of the following ultrasound-guided injection interventions:
Group 1 - Hyaluronic Acid
Participants in the HA group will receive 2-3 mL of high-molecular-weight hyaluronic acid. The HA will be injected perineurally with the intention of creating a gliding plane around the median nerve and reducing perineural adhesions.
Group 2 - Corticosteroid
Participants in the corticosteroid group will receive triamcinolone acetonide 40 mg mixed with 1 mL of lidocaine. The injection will be administered into the carpal tunnel under ultrasound guidance.
Group 3 - 5% Glucose
Participants in the 5% glucose group will receive 5 mL of 5% glucose (D5W) by ultrasound-guided hydrodissection around the median nerve. The procedure will aim to separate the median nerve from the flexor retinaculum and surrounding tissues.
Follow-Up and Outcome Assessment
Participants will be reassessed 3 months after the injection. Follow-up assessment will include repetition of the clinical, electrophysiological, and ultrasonographic evaluations.
Clinical outcomes will be assessed using Phalen's test and Tinel's sign. Electrophysiological outcomes will be evaluated using nerve conduction studies, including the relevant median sensory and motor nerve conduction parameters. Ultrasonographic follow-up will include reassessment of the median nerve cross-sectional area.
The study will compare the findings obtained after treatment among the three intervention groups to assess differences in treatment response.
Study Duration
The study is planned to continue for at least 12 months, from January 2026 to December 2026.
Potential Benefits
The study is intended to provide comparative information regarding three non-surgical injection approaches for the management of mild to moderate CTS. The findings may help in evaluating the relative clinical, electrophysiological, and ultrasonographic responses associated with hyaluronic acid, corticosteroid, and 5% glucose injections.
Potential Risks
The protocol identifies infection as a potential risk associated with injection procedures. Sterile equipment and sterile technique will be used to minimize this risk. Any unexpected risk that becomes apparent during the study will be communicated promptly to the participant and the relevant ethical committee.
Ethical Considerations
Informed consent will be obtained from all participants before their inclusion in the study. Participant privacy and confidentiality will be maintained. Patient names will be removed from electrophysiological and ultrasound reports to protect participant identity. Any unexpected risks arising during the course of the research will be promptly communicated to the participant and the ethical committee.
The results of the study will be tabulated and statistically analyzed, and the findings will subsequently be discussed in relation to available published data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults aged 18-70 years. Clinical symptoms of carpal tunnel syndrome for ≥6 weeks. Electrophysiological confirmation of mild to moderate carpal tunnel syndrome. Ability to provide .
-
Exclusion Criteria:
Local infection or coagulopathy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 2-3 mL of high-molecular-weight hyaluronic acid by ultrasound-guided perineural injection around the median nerve. The injection will be performed under sterile conditions. Participants will be positioned either supine or seated with the forearm supinated. The ultrasound probe will be positioned transversely over the inlet of the carpal tunnel, and an in-plane ulnar approach will be used. Care will be taken to avoid piercing the median nerve.
Drug: Hyaluronic Acid- corticosteroid- 5% glucose
Participants will receive triamcinolone acetonide 40 mg mixed with 1 mL of lidocaine by ultrasound-guided injection into the carpal tunnel. The injection will be performed under sterile conditions. Participants will be positioned either supine or seated with the forearm supinated. The ultrasound probe will be positioned transversely over the inlet of the carpal tunnel, and an in-plane ulnar approach will be used. Care will be taken to avoid piercing the median nerve.
Drug: Hyaluronic Acid- corticosteroid- 5% glucose
Participants will receive 5 mL of 5% glucose (D5W) by ultrasound-guided hydrodissection around the median nerve. The injection will be performed under sterile conditions. Participants will be positioned either supine or seated with the forearm supinated. The ultrasound probe will be positioned transversely over the inlet of the carpal tunnel, and an in-plane ulnar approach will be used. Care will be taken to avoid piercing the median nerve.
Drug: Hyaluronic Acid- corticosteroid- 5% glucose
All injections will be performed under sterile conditions with ultrasound guidance. The participant will be positioned either supine or seated with the forearm supinated. The ultrasound probe will be positioned transversely over the inlet of the carpal tunnel, and an in-plane ulnar approach will be used. Particular care will be taken to avoid piercing the median nerve. Participants will receive one of the following ultrasound-guided injection interventions: Group 1 - Hyaluronic Acid Participants in the HA group will receive 2-3 mL of high-molecular-weight hyaluronic acid. The HA will be injected perineurally with the intention of creating a gliding plane around the median nerve and reducing perineural adhesions. Group 2 - Corticosteroid Participants in the corticosteroid group will receive triamcinolone acetonide 40 mg mixed with 1 mL of lidocaine.
Change in median nerve cross-sectional area (CSA)
Median nerve cross-sectional area measured by ultrasound at baseline and 3 months after treatment, comparing the change among the three treatment groups.
Time frame: Baseline to 3 months after injection
Plan to share: No
Ran from Mar 2026 to primary completion in Jun 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.